LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Hepatitis B Surface Antibody, Quantitative

CPT: 86317
Print Share


  • Anti-HBs
  • Antibody to Hepatitis B Surface Antigen

Expected Turnaround Time

1 - 2 days

Related Documents

Specimen Requirements


Serum or plasma


1 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)


Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube


If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Non-EDTA plasma specimen; PST gel-barrier tube

Test Details


Hepatitis B surface antibody (anti-HBs) level can be measured to determine if vaccination is needed. Following a vaccination regimen, anti-HBs can be measured to determine if protective immunity has been achieved.


Presence of anti-HBs is not an absolute indicator of resolved hepatitis infection nor of protection from future infection. Since there are different serologic subtypes of hepatitis B virus, it is possible (and has been reported) for a patient to have antibody to one surface antigen type and to be acutely infected with a virus of a different subtype. Thus, a patient may have coexisting HBsAg and anti-HBs. Transfused individuals or hemophiliacs receiving plasma components may give false-positive tests for antibody to hepatitis B surface antigen.


Immunochemiluminometric assay (ICMA)

Reference Interval

• Inconsistent with immunity: 0.0−9.9 mIU/mL

• Consistent with immunity: >9.9 mIU/mL


Devine P, Taswell HF, Moore SB, Gilchrist GS, Jacobson TM. Passively acquired antibody to hepatitis B surface antigen. Pitfall in evaluating immunity to hepatitis B viral infections. Arch Pathol Lab Med. 1989 May; 113(5):529-531. 2712676
Edwards MS. Hepatitis B serology—Help in interpretation. Pediatr Clin North Am. 1988; 35(3):503-515 (review). 3287312
Foutch PG, Carey WD, Tabor E, et al. Concomitant hepatitis B surface antigen and antibody in 13 patients. Ann Intern Med. 1983 Oct; 99(4):460-463. 6625377
Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982 Sep; 97(3):362-366. 6810736
Lee HS, Vyas GN. Diagnosis of viral hepatitis. Clin Lab Med. 1987 Dec; 7(4):741-757. 3319367
Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1990 Feb 9; 39(RR-2):1-26. 2153904
Swenson PD, Escobar MR, Carithers RL Jr, Sobieski TJ 3rd. Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection. J Clin Microbiol. 1983 Aug; 18(2):305-309. 6619284


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
006530 Hepatitis B Surf Ab Quant 16935-9 006531 Hepatitis B Surf Ab Quant mIU/mL 16935-9

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at